纤溶酶原激活物抑制物1 Plasminogen activator inhibitor 1英语短句 例句大全

纤溶酶原激活物抑制物1,Plasminogen activator inhibitor 1

1)Plasminogen activator inhibitor 1纤溶酶原激活物抑制物1

1.Effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1 and thromboxane B2 in type 2 diabetes mellitus;银杏叶提取物对糖尿病纤溶酶原激活物抑制物1及凝血噁烷B2影响

2.Effect of ageing and alcohol on plasminogen activator inhibitor 1 mRNA expression in rat s liver and cerebral cortex;增龄及乙醇对大鼠肝和大脑纤溶酶原激活物抑制物1mRNA表达的影响

3.Relationship between plasminogen activator inhibitor 1 and neuroblastoma;纤溶酶原激活物抑制物1与神经母细胞瘤

英文短句/例句

1.Relationship between plasminogen activator inhibitor 1 and neuroblastoma纤溶酶原激活物抑制物1与神经母细胞瘤

2.Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases纤溶酶原激活物抑制剂-1与心血管疾病

3.Inhibitory effect of green tea polyphenols on plasminogen activator inhibitor-1 expression绿茶多酚对纤溶酶原激活物抑制剂-1表达影响

4.The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用

5.Research Progress of Plasminogen Activator Inhibitor One in Gestational Diabetes Mellitus纤溶酶原激活物抑制剂-1（PAI-1）与妊娠期糖尿病的研究

6.Change and Implication of PAI-1 in Coronary Heart Disease Patients after Glucose Load冠心病患者糖负荷后纤溶酶原激活物抑制物-1的变化及意义

7.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究

8.The relation of plasma plasminogen activator inhibitor activity and coronary heart disease纤溶酶原激活抑制物活性与冠心病发病关系

9.The Effect of Astragalus and Safflower Mixture on Expression of Plasminogen Activator Inhibitor 1 in Renal Tubulointerstitial Fibrosis in Rats with Unilateral Ureteral Obstruction;芪红合剂对肾间质纤维化模型大鼠肾组织中纤溶酶原激活物抑制物-1表达的影响

10.Plasma Concentrations of Matrix Metalloproteinase-9 and Plasminogen Activator Inhibitor-1 in Acute Coronary Syndromes;急性冠脉综合征金属蛋白酶-9与纤溶酶原激活物抑制物-1的关系研究

11.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究

12.The Varity and Mechnisim of the Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes with Hypertriglyceridemia;伴高甘油三酯血症的2型糖尿病纤溶酶原激活物抑制物-1水平变化及机制探讨

13.A Preliminary Study on the Relationship between TM、PAI-1 and Carotid Artery Lesion in DM;血栓调节蛋白、纤溶酶原激活物抑制物-1与糖尿病颈动脉病变的关系

14.The clinical analysis on the homocystein and PAI-1 of 80 cases of the patients with metabolism synthesis drafts the merge apoplexy80例代谢综合征合并脑卒中患者同型半胱氨酸及纤溶酶原激活物抑制物-1检测分析

15.Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析

16.A Case of Deficiency of Plasma Plasminogen Activator Inhibitor 1, Its Diagnosis, Treatment and Study on Molecular Abnormality遗传性纤溶酶原激活剂抑制物-1缺乏症的诊断、治疗及发病机理的研究

17.Regulation of Plasminogen Activator Inhibitor-1 Expression during 3T3-L1 Adipocytes Differentiation;脂肪细胞分化过程中纤溶酶原激活剂抑制物-1基因的表达调控研究

18.The Study on the Effect of Tissue-type Plasminogen Activator and Its Inhibitor-1 on the Formation of Pulmonary Thromboembolism;组织型纤溶酶原激活物及其抑制剂-1对肺血栓栓塞症形成影响的探讨

相关短句/例句

plasminogen activator inhibitor-1纤溶酶原激活物抑制物1

1.Effects of Dahuang Zhechong Pill on expressions of tissue inhibitor of metalloproteinase-1 andplasminogen activator inhibitor-1 in rats with glomerulosclerosis;大黄虫丸对肾小球硬化大鼠纤溶酶原激活物抑制物1和金属蛋白酶1组织抑制剂mRNA表达的影响

2.Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.纤溶酶原激活物抑制物1(PAI-1)是血浆纤维蛋白溶解系统的重要组成物之一,对维持血浆纤溶系统的稳定起重要作用。

3.Objective To explore the relationship between the level ofplasminogen activator inhibitor-1(PAI-1)and the extent of coronary lesions in coronary heart disease(CHD)patients accompanied with Type 2 diabetes mellitus(T2DM).目的研究合并2型糖尿病的冠心病患者冠脉病变程度与血浆纤溶酶原激活物抑制物1(plasminogen acti-vator inhibitor-1,PAI-1)水平的相关性。

3)Plasminogen activator inhibitor1纤溶酶原激活物抑制物1

4)plasminogen activator inhibitor 1纤溶酶原激活抑制物1

5)atherrosclerosis纤溶酶原激活抑制物-1

1.Objective Raisingatherrosclerosis model, to observe the the local expression of angiotensin II (Ang II ), transforming growth factor-β1 (TGF-β1)、plasminogen activator inhibitor-1 (PAI-1) and type IV collagen in renal tissue and to approach the renal protective effect of Captopril and Valsartan through blocking renin-angiotonin system(RAS) on various level.目的建立动脉粥样硬化(atherosclerosis,AS)模型,观察在AS形成时肾脏组织中血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、纤溶酶原激活抑制物-1(plasminogen activator inhibitor-1,PAI-1)和Ⅳ型胶原蛋白的表达以及卡托普利与缬沙坦从不同水平阻断肾素-血管紧张素系统(renin-angiotonin system,RAS)后对肾脏的保护作用。

6)plasminogen activator inhibitor-1/tissue plasminogen activator纤溶酶原激活物抑制物-1/组织纤溶酶原激活物

延伸阅读

纤溶酶原激活剂分子式：CAS号：性质：是一组蛋白酶，使纤溶酶激活生成有活性的纤溶酶。它们主要包括：(1)组织纤溶酶激动剂(tPA)，一种丝氨酸蛋白酶，创伤或应激时从血管内皮释放入血，只有同纤维蛋白结合时才有激活纤溶酶原的活性；(2)尿激酶，对纤维蛋白选择性较低，是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌，可能参与清除沉积在管道内的纤维蛋白；(3)链激酶，临床上用于裂解纤维蛋白，其选择性较差，可作用于液相中的纤溶酶原，也可作用于纤维蛋白血块中的纤溶酶原，链激酶不是蛋白酶，但与纤溶酶原结合成复合物后构象改变，显示蛋白水解酶活性。